Last reviewed · How we verify
Motavizumab, palivizumab
At a glance
| Generic name | Motavizumab, palivizumab |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children (PHASE1, PHASE2)
- Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season (PHASE2)
- A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Motavizumab, palivizumab CI brief — competitive landscape report
- Motavizumab, palivizumab updates RSS · CI watch RSS
- MedImmune LLC portfolio CI